<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Diabetes Research Connection on Medium]]></title>
        <description><![CDATA[Stories by Diabetes Research Connection on Medium]]></description>
        <link>https://medium.com/@susie_68451?source=rss-cd0751b447bb------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*X0zqQNp03QwN1s7lNE-5vA.jpeg</url>
            <title>Stories by Diabetes Research Connection on Medium</title>
            <link>https://medium.com/@susie_68451?source=rss-cd0751b447bb------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 05:24:46 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@susie_68451/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Breaking Down the Prevalence of Type 1 Diabetes]]></title>
            <link>https://medium.com/@susie_68451/breaking-down-the-prevalence-of-type-1-diabetes-66cd12950b0c?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/66cd12950b0c</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[t1d]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Mon, 04 Jun 2018 09:34:32 GMT</pubDate>
            <atom:updated>2018-06-09T05:00:29.346Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*x6EbsYWudsCa634tMtwJrg.jpeg" /></figure><p>Diabetes affects people of all ages and races throughout the United States, but just how many people are impacted? According to a <a href="https://www.clinicaladvisor.com/diabetes-resource-center/cdc-report-diabetes-by-type-us-adults/article/760827/">self-report study</a> of 33,028 adults with a response rate of 54.3%, approximately 21 million adults (8.6%) in the United States were living with type 2 diabetes in 2016, and approximately 1.3 million (0.55%) were living with type 1 diabetes.</p><p>The study, conducted by the Centers for Disease Control and Prevention (CDC) asked participants a variety of questions regarding being diagnosed with diabetes and what methods were used to manage it. Responses were classified as type 1, type 2, or “other” type of diabetes. There were 182 participants who reported having type 1 diabetes but did not claim to take any type of insulin, so they were categorized as type 2 respondents. Out of the 33,028 participants, 3,519 reported having diabetes, and 211 of those reported having type 1 diabetes. The study also found that T1D was more prevalent in men than women (0.64% vs. 0.46%), and as well as in non-Hispanic whites versus Hispanics (0.67% and 0.22% respectively).</p><p>Study authors hope that “knowledge about national prevalence of type 1 and type 2 diabetes might facilitate assessment of the long-term cost-effectiveness of public health interventions and policies aimed at improving diabetes management and help to prioritize national plans for future type-specific health services.”</p><p>Though it may seem like a small percentage who have T1D, it is still more than a million people who struggle each day with this disease, and more than a million people who would benefit from advanced research and treatment options. The <a href="http://diabetesresearchconnection.org/">Diabetes Research Connection</a> seeks to further knowledge, research, and interventions regarding type 1 diabetes as well and supports novel research studies focused on this condition. Early career scientists can receive valuable funding through the DRC to support their research projects. Check out the current studies and support these efforts by visiting <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/breaking-prevalence-type-1-diabetes/"><em>diabetesresearchconnection.org</em></a><em> on June 4, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=66cd12950b0c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Are Artificial Pancreas Systems Effective in Treating Type 1 Diabetes?]]></title>
            <link>https://medium.com/@susie_68451/are-artificial-pancreas-systems-effective-in-treating-type-1-diabetes-2a2f6b75bf7b?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/2a2f6b75bf7b</guid>
            <category><![CDATA[research]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[nonprofit]]></category>
            <category><![CDATA[diabetes]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Fri, 25 May 2018 07:29:39 GMT</pubDate>
            <atom:updated>2018-06-09T04:58:56.497Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PWXl2kB8WowvBV2PI6hBOg.jpeg" /></figure><p>There are many options available for treating type 1 diabetes from regular finger pricks and injections of insulin to continuous glucose monitoring systems to artificial pancreases and more. However, each person must find what works best for them in the management of their disease.</p><p>One treatment method that has undergone recent study is the use of artificial pancreas systems. <a href="https://www.clinicaladvisor.com/diabetes-resource-center/artificial-pancreas-systems-safe-for-type-1-diabetes/article/761857/">According to researchers</a> led by Eleni Bekiari, MD, Ph.D., at the Clinical Research and Evidence-Based Medicine Unit at the Aristotle University of Thessaloniki in Greece, these systems can provide positive results for some patients in managing their T1D. Throughout a series of 40 studies encompassing 1027 participants, artificial pancreas systems were found to not only be safe but also an effective line of treatment.</p><p>The study compared several different factors of single and dual hormone systems but mainly focused on the percentage of time normal glycemic levels were maintained. These results were measured against patients using standard insulin-based treatments. The study found that those individuals using the artificial pancreas systems experienced higher durations of time where their blood sugar levels were in the normoglycemic range, including overnight — 15.15% for artificial pancreas systems versus 9.62% for insulin-based treatment. There was also less deviation between blood sugar levels.</p><p>The researchers found that “artificial pancreas systems are an efficacious and safe approach for treating outpatients with type 1 diabetes.” More research and clinical trials are necessary to further explore the benefits and long-term outcomes of these systems. The <a href="http://diabetesresearchconnection.org/">Diabetes Research Connection</a> is committed to supporting early career scientists in advancing their research and delving more deeply into topics related to the diagnosis, treatment, and management of type 1 diabetes. The DRC provides essential funding for researchers to carry out peer-reviewed, novel research projects. To learn more about current projects and support these efforts, visit <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/artificial-pancreas-systems-effective-treating-type-1-diabetes/"><em>diabetesresearchconnection.org</em></a><em> on May 25, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2a2f6b75bf7b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Viruses May Cause T1D and Other Autoimmune Diseases]]></title>
            <link>https://medium.com/@susie_68451/viruses-may-cause-t1d-and-other-autoimmune-diseases-c24b1787dc51?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/c24b1787dc51</guid>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[virus]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Tue, 22 May 2018 03:12:08 GMT</pubDate>
            <atom:updated>2018-06-09T04:57:00.928Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*qr7z6TlHH5g3Os_L0hEPvg.jpeg" /></figure><p>Viruses are the cause of many health conditions and affect the body in different ways. As scientists learn more about these viruses, they can develop targeted strategies for preventing and treating them. A major breakthrough was recently discovered involving a very common virus known as the Epstein-Barr Virus or EBV.</p><p>EBV is most commonly known for causing mononucleosis (mono) or the “kissing disease” since it is often transmitted via saliva. By age 20, more than 90 percent of the population in developed countries will be infected by the disease. This rate spikes in under-developed countries with more than 90 percent of the population being affected by age 2. There is no cure for the virus — it remains in the body for life, though may not have a noticeable impact.</p><p>However, researchers have found that the effect it can have at a cellular level may be more significant than previously realized. Scientists from the Cincinnati Children’s Hospital’s Center for Autoimmune Genomics and Etiology have <a href="https://www.sciencedaily.com/releases/2018/04/180416121606.htm">published a study</a> potentially linking EBV to seven diseases, including T1D. One of the Diabetes Research Connection’s own Scientific Review Committee members, Matthias Von Herrath, was an author on an article <a href="https://www.nature.com/articles/s41588-018-0102-3">cited by the study</a> in its research.</p><p>Typically, the body responds to viruses by increasing the production of antibodies by B cells. These antibodies then attack and destroy the virus. However, with EBV, the virus actually takes over the B cells and re-programs them using transcription factors. This alters the way that B cells respond and can change their basic function, which may increase the risk of developing other diseases. The scientists have narrowed it down to one factor in particular — the EBNA2 protein.</p><p>Transcription factors associated with this protein attach to and change sections of person’s genetic code. Depending on where they attach, it could contribute to different diseases including T1D, lupus, multiple sclerosis, rheumatoid arthritis, celiac disease, and more. Identifying what is happening on a cellular level could help researchers to develop more targeted treatment options and potential cures for these diseases. The study also opens doors for more in-depth research regarding how transcription factors may affect other gene variants and diseases.</p><p>These findings are very encouraging in better understanding some of the underlying factors that may contribute to T1D. More research is necessary to explore each disease in particular and the potential impact from EBV and the EBNA2 protein. The <a href="https://diabetesresearchconnection.org/">Diabetes Research Connection</a> is excited to see where these discoveries may lead moving forward and how it could change the future of T1D treatment. The DRC provides funding to early-career scientists pursuing novel research studies on type 1 diabetes to improve prevention strategies, treatment options, and management techniques as well as potentially find a cure. Learn more about current projects and provide support by visiting <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/viruses-may-cause-t1d-autoimmune-diseases/"><em>diabetesresearchconnection.org</em></a><em> on May 22, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c24b1787dc51" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Oxygen Supply May be Key in Supporting Islet Transplantation]]></title>
            <link>https://medium.com/@susie_68451/oxygen-supply-may-be-key-in-supporting-islet-transplantation-9f59571b92d8?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/9f59571b92d8</guid>
            <category><![CDATA[type-1-diabetes]]></category>
            <category><![CDATA[cells]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[nonprofit]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Tue, 15 May 2018 18:27:10 GMT</pubDate>
            <atom:updated>2018-06-09T04:54:17.364Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-VPTbmyR4d-2Uu3KBqW4RA.jpeg" /></figure><p>One of the strategies scientists have focused on in the treatment of type 1 diabetes is transplanting healthy islet cells into the body to naturally produce insulin and manage blood glucose levels. These cells may be lab-generated or come from a donor. However, a major challenge has been conducting these transplants without reliance on immunosuppressants which can compromise overall patient health and complicate treatment.</p><p>In order to overcome this obstacle, researchers have created encapsulation devices to protect transplanted islet cells from attack by the body without using immunosuppressants. But with these devices, the lifespan of cells has been limited, in part due to poor oxygen supply. The devices often limit access to oxygen or restrict diffusion.</p><p>A <a href="https://www.nature.com/articles/s41598-018-23862-w?elqTrackId=165994ccdb00416ab4f1321dc325b49b&amp;elq=7e0eec95269d4595b4154c14987d7c48&amp;elqaid=21932&amp;elqat=1&amp;elqCampaignId=10602">new study</a> has found that surrounding islet cells in an oxygen-permeable membrane and equipping the encapsulation device with an oxygen chamber can provide the necessary oxygen supply to keep cells functional and viable. Scientists experimented with varying levels of islet cell surface density and oxygen partial pressure (pO2). The chamber allowed oxygen to be diffused throughout the highly concentrated alginate slab of islet cells.</p><p>The results showed that an average of 88% of islet cells maintained their viability and supported normoglycemic levels when tested in diabetic rats. Due to the continuous diffusion of oxygen, the chamber needs to be refilled daily through a subcutaneous port. Of the 137 rats in the trial, 66 remained normoglycemic for at least eight weeks. Some remained normoglycemic for up to 238 days, at which point the device was electively removed. Upon explanation, rats experienced hyperglycemia. When given intravenous glucose tolerance tests, results from rats with the implanted device were not significantly different than those of non-diabetic rats.</p><p>Researchers are currently exploring opportunities to decrease the size of the device while achieving greater islet density and continued viability. This study demonstrates how technology is advancing to create more options for treating and potentially curing type 1 diabetes with fewer complications and undesirable side effects.</p><p>Though not involved with this particular study, the <a href="https://diabetesresearchconnection.org/">Diabetes Research Connection</a> is committed to supporting novel research for type 1 diabetes in an effort to prevent and cure the disease as well as reduce complications and improve quality of life for those living with type 1 diabetes. Visit us online at <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a> to learn more about current research projects and provide support for these initiatives.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/oxygen-supply-may-key-supporting-islet-transplantation/"><em>diabetesresearchconnection.org</em></a><em> on May 15, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9f59571b92d8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What You Need to Know About Hypoglycemia Unawareness]]></title>
            <link>https://medium.com/@susie_68451/what-you-need-to-know-about-hypoglycemia-unawareness-53771e739088?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/53771e739088</guid>
            <category><![CDATA[insulin]]></category>
            <category><![CDATA[t1d]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Thu, 19 Apr 2018 04:55:53 GMT</pubDate>
            <atom:updated>2018-06-09T04:41:16.539Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wdFpUxc2orpl4gRCxH6NxA.jpeg" /></figure><p>Many people are aware of warning signs that their blood sugar is too low. They experience sweating, shakiness, hunger, or dizziness. They may also feel confused, sleepy, or weak. As a result, they eat or drink something to bring their blood sugar back up. However, some people with diabetes are <a href="https://diatribe.org/hypoglycemia-unawareness-101">unaware of the signs of hypoglycemia</a> or low blood sugar — not that they don’t know what the symptoms are, they just don’t experience or perceive them. This can be dangerous to their health and well-being.</p><p>There are numerous risk factors for hypoglycemia including:</p><ul><li>Sleeping: Blood sugar may drop while sleeping and occur frequently enough that it alters their ability to detect symptoms while awake.</li><li>Time: The longer someone lives with diabetes, the less sensitive they may become to low blood sugar. People who have used insulin for 20 years or more tend to be at greater risk.</li><li>Age: Older adults may experience cognitive changes that affect their ability to recognize hypoglycemia.</li><li>Exercise: Rigorous exercise can affect blood sugar levels up to 15 hours later.</li><li>Alcohol: When the liver is occupied with processing alcohol, it may not be able to release glucose as effectively resulting in hypoglycemia.</li><li>Prescription Drugs: Certain medications may affect a person’s ability to recognize symptoms of low blood sugar.</li></ul><p>However, there are several ways to manage hypoglycemia unawareness and be proactive in keeping blood sugar in check.</p><ul><li>Testing blood sugar more frequently throughout the day can help individuals to recognize when their blood sugar is getting low so they can treat it early.</li><li>Using a continuous glucose monitoring system (CGM) or automatic insulin delivery (AID) device can help with tracking blood sugar trends and administering or suspending insulin as necessary. This can help to achieve more stable blood glucose levels and reduce incidences of hypoglycemia.</li><li>Using long-acting or fast-acting insulin analogs may help as well, especially at night and during meal times.</li><li>Targeted training on improved insulin usage and how to be proactive in managing blood sugar can reduce risk. Working with a certified diabetes educator can be very beneficial in managing hypoglycemia unawareness.</li></ul><p>Effectively managing blood sugar is an essential part of living with type 1 diabetes, but that can be difficult, especially with so many contributing factors and the fact that every person is different. That is what makes the work of the <a href="https://diabetesresearchconnection.org/">Diabetes Research Connection</a> (DRC) even more important. The DRC provides vital funding for early career scientists to pursue novel research projects geared toward diagnosing, treating, and curing type 1 diabetes, as well as improving quality of life for individuals living with the disease. Their studies have the potential to make a difference in the future of type 1 diabetes care. Find out more about current projects and how to support these efforts by visiting <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/need-know-hypoglycemia-unawareness/"><em>diabetesresearchconnection.org</em></a><em> on April 19, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=53771e739088" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Examining the Impact of Adding SGLT2 Inhibitors to T1D Treatment]]></title>
            <link>https://medium.com/@susie_68451/examining-the-impact-of-adding-sglt2-inhibitors-to-t1d-treatment-934762d7634d?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/934762d7634d</guid>
            <category><![CDATA[autoimmune-disease]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[insulin]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <category><![CDATA[research]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Wed, 11 Apr 2018 21:43:49 GMT</pubDate>
            <atom:updated>2018-06-09T04:52:04.491Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*0FyBemS5QW3fOsg3jdnRfw.jpeg" /></figure><p>For individuals living with type 1 diabetes, every day consists of checking their blood glucose levels, monitoring what they eat, and taking the appropriate amount of insulin to keep their blood sugar levels stable. However, long-term use of insulin can lead to undesirable dose-dependent side effects such as weight gain and hypoglycemia. Since there is currently no cure for T1D, these effects can be concerning because individuals must continue to take insulin for the foreseeable future.</p><p>Looking for a way to curb these effects, a <a href="http://www.diabetesincontrol.com/sglt2-inhibitors-in-treatment-of-type-1/">recent study</a> examined the efficacy of adding sodium-glucose cotransporter 2 inhibitors (SGLT2) to treatment for T1D. The medications used for the study were canagliflozin, empagliflozin, sotagliflozin, and dapagliflozin. Four different randomized controlled trials were conducted.</p><p>The results showed numerous positive changes when insulin use was combined with one of the four medications. There were statistically significant reductions in A1c levels as well as weight gain. In addition, the amount of insulin needed also decreased. While each medication led to different results, they all had similar effects on reducing these issues. Furthermore, the addition of these medications to treatment did not lead to any significant changes in risk associated with hypoglycemia, adverse events, or episodes of DKA.</p><p>This was a small study, so more extensive testing is necessary to evaluate the effects of SGLT2 inhibitors on T1D treatment on a larger scale. However, these initial tests show promising results and support for conducting more thorough investigations.</p><p>It is these types of forward-thinking research studies aimed at improving treatment and quality life for individuals living with T1D that the Diabetes Research Connection (DRC) is passionate about supporting. Though not involved in this study, the DRC has supported dozens of early career scientists by providing funding for novel research. These studies may lead to new breakthroughs or areas that can continue to be explored more deeply. To learn more about current projects and support these efforts, visit <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/examining-impact-adding-sglt2-inhibitors-t1d-treatment/"><em>diabetesresearchconnection.org</em></a><em> on April 11, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=934762d7634d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Improving PD-L1 Levels to Treat Type 1 Diabetes]]></title>
            <link>https://medium.com/@susie_68451/improving-pd-l1-levels-to-treat-type-1-diabetes-5d8b5d8abba7?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/5d8b5d8abba7</guid>
            <category><![CDATA[t1d]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <category><![CDATA[diabetes]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Thu, 29 Mar 2018 11:01:40 GMT</pubDate>
            <atom:updated>2018-06-09T05:02:32.640Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*x_nypRsywcNCS8byYdbeow.jpeg" /></figure><p>A major obstacle that researchers face in treating type 1 diabetes (T1D) is the body’s own immune system. In individuals with T1D, the immune system destroys insulin-producing beta cells whether naturally occurring or introduced through novel therapeutic approaches. The use of anti-rejection drugs to protect newly injected or created cells can be hard to the body and contribute to undesirable side effects.</p><p>However, researchers at Boston Children’s Hospital are <a href="https://www.drugtargetreview.com/news/27501/reverse-diabetes-blood-stem-cells/">studying a new approach</a> to treating — and potentially curing — T1D. They found that in individuals with T1D have a deficiency of PD-L1, a protein that helps prevent autoimmune reactions by binding to PD-1 receptors. By treating blood stem cells using gene therapy or a cocktail of small molecules, they were able to increase PD-L1 production. In turn, this helped to reverse hyperglycemia and better manage blood sugar levels.</p><p>In an experiment using mice with diabetes, “almost all the mice were cured of diabetes in the short term, and one-third maintained normal blood sugar levels for the duration of their lives.” In addition, the risk of adverse events is practically eliminated since the therapy uses the patients’ own cells. Though immunotherapies have been used before in an effort to treat T1D, they have not been targeted specifically for diabetes, whereas in this study, they are.</p><p>The research team has already met with the U.S. Food and Drug Administration for a pre-investigational new drug meeting regarding the combination of small-molecules used during the mouse trials in order to begin the approval process for human clinical trials.</p><p>This is an exciting step toward advancing treatment options for type 1 diabetes and potentially reversing the disease. More research is needed to determine how long the effects last and how often treatment would be needed.</p><p>The <a href="https://diabetesresearchconnection.org/">Diabetes Research Connection</a> (DRC) is interested to see how the study progresses in the future and what it could mean for individuals living with type 1 diabetes. Though not involved with this particular project, the DRC supports early career scientists in pursuing novel research studies geared toward preventing, treating, and curing T1D, as well as improving quality of life for those living with the disease. Learn more about these researchers and their projects by visiting <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/improving-pd-l1-levels-treat-type-1-diabetes/"><em>diabetesresearchconnection.org</em></a><em> on March 29, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5d8b5d8abba7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Exploring Beta Cell Regeneration in Treating Type 1 Diabetes]]></title>
            <link>https://medium.com/@susie_68451/exploring-beta-cell-regeneration-in-treating-type-1-diabetes-770921bf1c47?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/770921bf1c47</guid>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Tue, 27 Mar 2018 23:14:29 GMT</pubDate>
            <atom:updated>2018-06-09T05:04:55.502Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*L7hy_WrGpwgjudNmhjDhWw.jpeg" /></figure><p>In individuals with type 1 diabetes (T1D), the body’s immune system mistakenly destroys insulin-producing beta cells necessary for managing blood sugar. Instead, patients must constantly monitor their own blood glucose levels and administer the proper dosage of insulin as necessary. In individuals without T1D, the pancreas does this automatically.</p><p>Some of the challenges that researchers have faced in trying to treat or cure T1D through cellular means is that the body may still reject these cells, there may be a shortage of donor cells, or the process of creating necessary beta cells can be complex. However, researchers at the Diabetes Research Institute at the University of Miami Miller School of Medicine may have found an effective way of using the body’s existing cell supply to <a href="https://www.drugtargetreview.com/news/30093/pancreatic-stem-cells-regenerate/">generate insulin-producing beta cells.</a></p><p>The researchers identified the exact location in the body of progenitor cells with the ability to develop into beta cells. When stimulated by bone morphogenetic protein 7 (BMP-7), a naturally occurring growth factor, the pancreatic cells differentiated into the necessary beta cells. This discovery could lead to a significant supply of new beta cells within patients’ own bodies, eliminating the need for donor cells and curbing other immune-related challenges of treatment.</p><p>This process still requires more in-depth study, but it could lead the way to new regenerative medicine strategies that stimulate insulin production more naturally. The researchers are currently exploring options to reduce the need for lifelong anti-rejection drugs by enhancing immune tolerance of the newly created cells.</p><p>This study is another step toward advancing the treatment of T1D and providing patients with more options for care. The more scientists learn about the causes and effects of T1D, the more they can target approaches to treatment.</p><p>The <a href="http://diabetesresearchconnection.org/">Diabetes Research Connection</a> (DRC) stays abreast of the latest developments in the field and encourages novel research projects by early-career scientists focused on T1D. The DRC raises funds through contributions by individuals, organizations, and foundations to support the advancement of these studies. Find out how you can get involved by visiting <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/exploring-beta-cell-regeneration-treating-type-1-diabetes/"><em>diabetesresearchconnection.org</em></a><em> on March 27, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=770921bf1c47" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Could Implantable Glucose Sensors be a Viable Option for Monitoring Blood Sugar?]]></title>
            <link>https://medium.com/@susie_68451/could-implantable-glucose-sensors-be-a-viable-option-for-monitoring-blood-sugar-4ceb8609949?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/4ceb8609949</guid>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[glucose-monitoring]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Wed, 21 Mar 2018 02:25:21 GMT</pubDate>
            <atom:updated>2018-06-09T05:07:18.057Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ktlenysgXJcYgZfI3X6sBg.jpeg" /></figure><p>Diabetes management has come a long way over the years. Some people have transitioned away from constant finger pricks and begun using continuous glucose monitoring (CGM) systems to track their blood sugar and alert them to episodes of hyperglycemia or hypoglycemia. However, not everyone has the same level of adherence to using this technology, so results can be inconsistent.</p><p>Researchers from <a href="https://www.healio.com/endocrinology/diabetes/news/in-the-journals/%7B1288c2be-b720-48a3-8b7a-1c934e19c1cd%7D/implantable-glucose-sensor-safe-accurate-in-type-1-type-2-diabetes">Diablo Clinical Research recently conducted a study</a> on the use of implantable, subcutaneous continuous glucose sensors for diabetes management. A small sensor was placed under the skin, and then a transmitter was positioned over top providing wireless power and transmission of data to a mobile app. The transmitter also vibrated to alert users of episodes of hyper- or hypoglycemia in addition to alerts being sent to the app.</p><p>There were 90 adults with type 1 and type 2 diabetes who participated in the nonrandomized, prospective, masked, single-arm study which lasted for 90 days. Sixty-one of the participants had type 1 diabetes. Individuals underwent accuracy assessment visits on days 1, 30, 60, and 90 to compare results of the implantable sensor versus a bedside glucose analyzer. In addition, some participants also partook in hyperglycemia and hypoglycemia challenges on days 30, 60, and 90. There were only eight participants who did not complete the study, and 12 reports of mild adverse events and two moderate adverse events.</p><p>Following the study, the results showed “more than 90% of continuous glucose monitoring system readings within 20% of reference values.” Furthermore, “the system correctly identified 93% of hypoglycemic events and 96% of hyperglycemic events by the reference glucose reader.” The implantable CGM system used was Eversense by Senseonics.</p><p>Additional clinical studies are necessary to further evaluate the safety and accuracy of the system and expand potential use to pediatric patients as well. However, preliminary results show high levels of safety and accuracy in this small study.</p><p>This is an exciting step toward providing individuals with T1D another option for managing diabetes allowing them to measure blood sugar levels more consistently and with less intervention. The <a href="https://diabetesresearchconnection.org/">Diabetes Research Connection</a> (DRC) is interested to see how this study advances moving forward and what it may mean for diabetes management in the future. The DRC raises funds for early career scientists to perform peer-reviewed, novel research designed to prevent and cure type 1 diabetes, minimize its complications, and improve quality of life for those living with the disease. To learn more and support these efforts, visit <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/implantable-glucose-sensors-viable-option-monitoring-blood-sugar/"><em>diabetesresearchconnection.org</em></a><em> on March 21, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4ceb8609949" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Brain Differences May Impact Ability to Recognize Low Blood Sugar]]></title>
            <link>https://medium.com/@susie_68451/brain-differences-may-impact-ability-to-recognize-low-blood-sugar-d59bef58adda?source=rss-cd0751b447bb------2</link>
            <guid isPermaLink="false">https://medium.com/p/d59bef58adda</guid>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[brain]]></category>
            <category><![CDATA[type-1-diabetes]]></category>
            <dc:creator><![CDATA[Diabetes Research Connection]]></dc:creator>
            <pubDate>Fri, 16 Feb 2018 04:38:57 GMT</pubDate>
            <atom:updated>2018-06-09T05:09:17.898Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*qKLhZB9MgN5ZShI15t95JQ.jpeg" /></figure><p>Healthy adults can typically recognize when their blood sugar may be becoming too low. It triggers physical symptoms such as dizziness, sweating, weakness, and rapid heartbeat, just to name a few. Plus, their body responds by producing glucose and initiating the brain to signal for food. However, in individuals with type 1 diabetes, the brain does not always respond in this way.</p><p>A <a href="https://news.yale.edu/2018/02/01/brain-scans-show-why-some-type-1-diabetics-miss-low-blood-sugar-cues">recent study</a> found that the areas of the brain activated by low blood sugar in adults without diabetes are not the same as those in adults with type 1 diabetes. In brain scans of non-diabetic adults, areas associated with reward, motivation, and decision making showed changes during brain scans. However, only half of the individuals with T1D experienced similar changes, and only in one area of the brain — the area associated with attention — and the other half experienced no changes. Their brain showed no noticeable response to having low blood sugar, which is why individuals may miss cues that others would typically pick up on.</p><p>According to Janice Hwang, M.D., assistant professor of medicine and first author on the study, “There is a progressive loss of coordinated brain response to low blood sugar as you go from healthy adult to aware to unaware. The first areas of the brain to go are associated with feeding behavior.” The researchers are hoping that these findings will lead to more effective ways of restoring low blood sugar awareness in individuals with T1D who have lost this awareness.</p><p>It is these types of discoveries that help to improve understanding of how T1D affects the brain and body and allows researchers to develop more effective ways of treating and managing the condition. The Diabetes Research Connection supports early career scientists striving to advance research regarding the treatment, prevention, diagnosis, and management of T1D. Researchers can receive up to $50,000 in funding to apply toward their project. To learn more or support these efforts, visit <a href="http://diabetesresearchconnection.org/">http://diabetesresearchconnection.org</a>.</p><p><em>Originally published at </em><a href="https://diabetesresearchconnection.org/brain-differences-may-impact-ability-recognize-low-blood-sugar/"><em>diabetesresearchconnection.org</em></a><em> on February 16, 2018.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d59bef58adda" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>